The combination treatment of anlotinib, penpulimab and capecitabine.
Phase 2Active 0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Neoplasms
Conditions
Nasopharyngeal Neoplasms
Trial Timeline
Sep 1, 2023 → Jul 1, 2026
NCT ID
NCT05807880About The combination treatment of anlotinib, penpulimab and capecitabine.
The combination treatment of anlotinib, penpulimab and capecitabine. is a phase 2 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Neoplasms. The current trial status is active. This product is registered under clinical trial identifier NCT05807880. Target conditions include Nasopharyngeal Neoplasms.
What happened to similar drugs?
0 of 13 similar drugs in Nasopharyngeal Neoplasms were approved
Approved (0) Terminated (0) Active (13)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
12
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05807880 | Phase 2 | Active |
Competing Products
20 competing products in Nasopharyngeal Neoplasms